Eli Lilly Retatrutide Results Propel Obesity Push

Eli Lilly said on May 21, 2026, that its investigational triple-agonist retatrutide produced clinically meaningful weight loss in the pivotal TRIUMPH-1 Phase 3 trial, a result the company said supports planned regulatory submissions and expands its obesity treatment portfolio.

TRIUMPH-1 Trial Results

Lilly announced topline results from the TRIUMPH-1 Phase 3 trial on May 21, showing that participants receiving the highest 12 mg weekly dose of retatrutide lost an average of 70.3 pounds, or 28.3% of body weight, at 80 weeks. Nearly half of these patients (45.3%) achieved at least 30% weight loss, a level Lilly described as comparable to bariatric surgery outcomes.

An extension cohort of participants with baseline body mass index (BMI) of 35 or higher continued treatment to 104 weeks, reaching an average loss of 85.0 pounds (30.3%). At the 4 mg dose, reached with a single escalation step, participants lost an average of 47.2 pounds (19.0%) at 80 weeks. Lilly reported a lower discontinuation rate due to adverse events at this dose compared with placebo.

All three tested dose regimens met the trial’s primary and key secondary weight-loss endpoints. Substantial proportions of participants surpassed prespecified thresholds of 10%, 20%, and 30% body-weight reduction.

Retatrutide is a first-in-class triple hormone receptor agonist targeting glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. TRIUMPH-1 enrolled adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity and no diabetes. Participants were randomized to once-weekly subcutaneous retatrutide at three dose levels or placebo.

Safety and Regulatory Implications

Lilly described retatrutide’s safety and tolerability profile as generally consistent with other incretin-based obesity therapies, with gastrointestinal side effects such as nausea, vomiting, and diarrhea driving most adverse events. The company noted that the 4 mg dose had a lower observed discontinuation rate due to adverse events than placebo.

Retatrutide remains investigational and is not approved by the U.S. Food and Drug Administration. Lilly said the TRIUMPH-1 results support planned regulatory submissions as it expands its obesity portfolio alongside existing products. The company markets Zepbound (tirzepatide), an injectable GLP-1/GIP agonist, and its oral GLP-1 candidate Foundayo (orforglipron) received FDA approval for weight loss on April 1, 2026.

Lilly positions retatrutide as a next-generation triple-agonist candidate intended to complement its injectable and oral options, particularly for patients seeking larger degrees of weight reduction. The trial’s topline results strengthen Lilly’s case for regulatory filings and deepen its presence in the obesity drug market.